Similarly, studies targeting GLI1/2 expression or function in tumor cells in vitro or in mouse models of cancer have shown remarkable anti-tumor efficacy and concluded to a pathogenic role for the HH pathway, although most studies targeted its main downstream effectors, not the pathway itself. The gene discussed is GLI1; the disease is neoplasm.